ArticleOncology letters2023

Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.

Shanmin Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.